Nucleate Podcast
Generative AI for Novel Therapies | Sean McClain, Absci
May 6, 2024
Sean McClain, Founder and CEO of AbSci, discusses using AI for drug development, the fusion of engineering and biology, the power of mentors in entrepreneurship, fostering diverse perspectives in leadership teams, and the challenges of pivoting to generative AI for antibodies.
53:13
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- AbSci uses generative AI to accelerate therapy development by engineering new medicines rapidly.
- CEO Sean McLean's fusion of engineering and biology principles drives AbSci's focus on reengineering E. coli for antibody production.
Deep dives
Abzai's Evolution into Leader in AI Drug Discovery
Abzai, initially a sin bio company, has transformed into an AI drug discovery leader. Leveraging generative AI models, Abzai designs improved biologics rapidly by engineering new medicines through AI to meet specific attributes. CEO Sean McLean's vision and embrace of the 'believe in the impossible' mantra led Abzai to raise over $500 million. The integration of AI with wet lab efforts marked a strategic shift towards innovative drug design.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
